Interferon gamma-producing ability in blood lymphocytes of patients with lung cancer through activation of the innate immune system by BCG cell wall skeleton.
An in vitro assay system was developed to assess the potency of the human innate immune system by measurement of IL-12, IL-18, IL-10 and IFNgamma in the supernatants of bacillus Calmette-Guerin cell wall skeleton (BCG-CWS)-stimulated blood samples. BCG-CWS is a ligand for Toll-like receptor (TLR) 2 and 4, and activates monocytes to macrophages (Mphi), and immature dendritic cells to mature antigen-presenting cells (APC). This system was found to allow the discrimination of immune suppressive states in patients with lung cancer from normal immune states in light of the cytokine profile. The following results were deduced from analyses of BCG-CWS-stimulated blood samples of lung cancer patients with reference to normal subjects. (1) The levels of production of IFNgamma and IL-10 by lymphocytes were decreased. (2) IL-12 p40 production by monocytes/Mphi was upregulated, while that of IL-10 was downregulated. (3) IL-18 was detected in all patients in a range similar to normal subjects. (4) Responses of lymphocytes to IL-2 and IL- 18 in terms of IFNgamma production were diminished. (5) The upregulated IL-12 levels were recovered to within the normal range in most patients after tumor resection. (6) Male patients showed more severe suppression of IL-12/IL-18-mediated IFNgamma production than female patients. Thus, the lesser IFNgamma production observed in patients' blood with high IL-12 p40 levels in response to BCG-CWS may reflect the production of p40 dimers or IL-23 instead of p70, or the presence of some unknown pathways to prohibit the interface between the innate and acquired immune systems. BCG-CWS-mediated Toll signaling may participate in IFNgamma induction for lymphocytes through Mphi/APC IL-12/I-18 modulation.
Matsumoto
M
M
Department of Immunology, Osaka Medical Center for Cancer and Cardiovascular Diseases, Japan.
Seya
T
T
Kikkawa
S
S
Tsuji
S
S
Shida
K
K
Nomura
M
M
Kurita-Taniguchi
M
M
Ohigashi
H
H
Yokouchi
H
H
Takami
K
K
Hayashi
A
A
Azuma
I
I
Masaoka
T
T
Kodama
K
K
Toyoshima
K
K
Higashiyama
M
M
Takami
H
H
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D000328:Adult; D000368:Aged; D001500:BCG Vaccine / Q000276:immunology* / Q000494:pharmacology; D017358:Cell Wall Skeleton / Q000276:immunology / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007107:Immune System / Q000187:drug effects / Q000378:metabolism*; D007371:Interferon-gamma / Q000096:biosynthesis* / Q000097:blood; D008175:Lung Neoplasms / Q000097:blood / Q000276:immunology*; D008214:Lymphocytes / Q000097:blood / Q000187:drug effects / Q000276:immunology*; D008297:Male; D008875:Middle Aged; D010361:Patients
D000276:Adjuvants, Immunologic; D001500:BCG Vaccine; D017358:Cell Wall Skeleton; D007371:Interferon-gamma